Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing ...
The FDA has approved cemiplimab-rwlc for adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk for ...
Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic ...
The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...
Comparing metagenomic profiles of the skin microbiome in immunosuppressed patients and those at high and low risk for cutaneous squamous cell carcinoma (SCC) revealed distinct expansions in fungal and ...
Phase 2 open-label study of brentuximab vedotin (BV) + pembrolizumab (pembro) in patients (pts) with treatment (tx)-naive metastatic head and neck squamous cell carcinoma (HNSCC). This is an ASCO ...
Efficacy analysis of neoadjuvant PD-1 inhibitor combined with chemotherapy in various subanatomical sites of locally advanced and recurrent resectable head and neck squamous cell carcinoma: A ...
The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of ...
Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...
The FDA has approved cemiplimab as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma. The US FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback